These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33606110)

  • 1. On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder.
    Uversky VN
    Arch Virol; 2021 May; 166(5):1283-1296. PubMed ID: 33606110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
    McLellan JS; Pancera M; Carrico C; Gorman J; Julien JP; Khayat R; Louder R; Pejchal R; Sastry M; Dai K; O'Dell S; Patel N; Shahzad-ul-Hussan S; Yang Y; Zhang B; Zhou T; Zhu J; Boyington JC; Chuang GY; Diwanji D; Georgiev I; Kwon YD; Lee D; Louder MK; Moquin S; Schmidt SD; Yang ZY; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Burton DR; Koff WC; Walker LM; Phogat S; Wyatt R; Orwenyo J; Wang LX; Arthos J; Bewley CA; Mascola JR; Nabel GJ; Schief WR; Ward AB; Wilson IA; Kwong PD
    Nature; 2011 Nov; 480(7377):336-43. PubMed ID: 22113616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 5. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress in the rational design of an AIDS vaccine.
    Nabel GJ; Kwong PD; Mascola JR
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2759-65. PubMed ID: 21893538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
    Liao HX; Lynch R; Zhou T; Gao F; Alam SM; Boyd SD; Fire AZ; Roskin KM; Schramm CA; Zhang Z; Zhu J; Shapiro L; ; Mullikin JC; Gnanakaran S; Hraber P; Wiehe K; Kelsoe G; Yang G; Xia SM; Montefiori DC; Parks R; Lloyd KE; Scearce RM; Soderberg KA; Cohen M; Kamanga G; Louder MK; Tran LM; Chen Y; Cai F; Chen S; Moquin S; Du X; Joyce MG; Srivatsan S; Zhang B; Zheng A; Shaw GM; Hahn BH; Kepler TB; Korber BT; Kwong PD; Mascola JR; Haynes BF
    Nature; 2013 Apr; 496(7446):469-76. PubMed ID: 23552890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiny steps towards an HIV vaccine.
    Willyard C
    Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.
    Zolla-Pazner S; Cardozo T
    Nat Rev Immunol; 2010 Jul; 10(7):527-35. PubMed ID: 20577269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine.
    Zhou T; Xu K
    Adv Exp Med Biol; 2018; 1075():73-95. PubMed ID: 30030790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.
    Gach JS; Mara KJV; LaBranche CC; van Gils MJ; McCoy LE; Klasse PJ; Montefiori DC; Sanders RW; Moore JP; Forthal DN
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31375582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
    Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
    Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
    Chen J; Kovacs JM; Peng H; Rits-Volloch S; Lu J; Park D; Zablowsky E; Seaman MS; Chen B
    Science; 2015 Jul; 349(6244):191-5. PubMed ID: 26113642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites.
    Acharya P; Luongo TS; Georgiev IS; Matz J; Schmidt SD; Louder MK; Kessler P; Yang Y; McKee K; O'Dell S; Chen L; Baty D; Chames P; Martin L; Mascola JR; Kwong PD
    J Virol; 2013 Sep; 87(18):10173-81. PubMed ID: 23843638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIDS/HIV. Converging on an HIV vaccine.
    Korber B; Gnanakaran S
    Science; 2011 Sep; 333(6049):1589-90. PubMed ID: 21921189
    [No Abstract]   [Full Text] [Related]  

  • 18. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
    Huang J; Kang BH; Pancera M; Lee JH; Tong T; Feng Y; Imamichi H; Georgiev IS; Chuang GY; Druz A; Doria-Rose NA; Laub L; Sliepen K; van Gils MJ; de la Peña AT; Derking R; Klasse PJ; Migueles SA; Bailer RT; Alam M; Pugach P; Haynes BF; Wyatt RT; Sanders RW; Binley JM; Ward AB; Mascola JR; Kwong PD; Connors M
    Nature; 2014 Nov; 515(7525):138-42. PubMed ID: 25186731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.
    Spurrier B; Sampson J; Gorny MK; Zolla-Pazner S; Kong XP
    J Virol; 2014 Apr; 88(8):4100-12. PubMed ID: 24478429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.